Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
| Revenue (TTM) | $730.02M |
| Gross Profit (TTM) | $348.11M |
| EBITDA | $194.51M |
| Operating Margin | 21.60% |
| Return on Equity | 10.30% |
| Return on Assets | 5.11% |
| Revenue/Share (TTM) | $16.10 |
| Book Value | $18.06 |
| Price-to-Book | 1.32 |
| Price-to-Sales (TTM) | 1.35 |
| EV/Revenue | 1.935 |
| EV/EBITDA | 7.32 |
| Quarterly Earnings Growth (YoY) | 4.70% |
| Quarterly Revenue Growth (YoY) | 5.40% |
| Shares Outstanding | $42.54M |
| Float | $31.29M |
| % Insiders | 30.81% |
| % Institutions | 69.66% |
Volatility is currently contracting
RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th, 2026, at 4:30 pm ET.
The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Net revenues of $183.9 million for the three months ended June 30, 2026 GAAP net income of $30.3 million, or $0.67 per share, for the second quarter Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, Calif.
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RANCHO CUCAMONGA, Calif., July 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its second quarter of 2026 ended June 30, 2026, after the market closes on Thursday, August 6, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m.
Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details remain unclear.
ARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.
Amphastar Pharmaceuticals NASDAQ: AMPH executives told investors at the Jefferies Healthcare Conference that the company is maintaining expectations for mid- to high-single-digit revenue growth in 2026, supported by a new generic launch, Primatene Mist growth and selected API sales from its China business.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AMPH and any ticker you trade — then tracks every position and per-strategy win rate.
